Literature DB >> 10517496

Thrombopoietin induces an SH2-containing protein, CIS1, which binds to Mpl: involvement of the ubiquitin proteosome pathway.

S Okabe1, T Tauchi, H Morita, H Ohashi, A Yoshimura, K Ohyashiki.   

Abstract

The interaction of thrombopoietin (TPO) with its receptor, Mpl, triggers growth and differentiation of megakaryocytes and their progenitors. The Mpl cytoplasmic domain controls this process through src homology 2 (SH2)-containing target molecules and their receptor docking sites. A novel cytokine inducible SH2-containing protein, CIS1, has been isolated. CIS1 is induced by interleukin-2 (IL-2), IL-3, GM-CSF, and erythropoietin (EPO), but not by IL-6, granulocyte colony-stimulating factor (G-CSF), or stem cell factor. To investigate the functional domains of Mpl for induction of CIS1, we examined FDCP-2 cell lines expressing seven carboxyl truncations of the human Mpl cytoplasmic domain. We found that the box1 and box2 regions of Mpl were necessary for induction of CIS1 after TPO stimulation. CIS1 was degraded very quickly and was found to be involved in the ubiquitin-proteosome pathway. A 4-hour depletion of TPO almost completely eliminated CIS1 protein; within 1 hour after TPO stimulation, CIS1 protein reappeared as 37- and 32-kDa proteins in the wild type Mpl-expressing FDCP-2 cells. Further, CIS1 was stably associated with tyrosine-phosphorylated Mpl. The SH2 domains of CIS1, constructed as glutathione S-transferase fusion protein, bound to activated Mpl in vitro. These results suggest that CIS1 may be an important signaling component downstream of Mpl and may regulate the proliferation and differentiation of hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517496     DOI: 10.1016/s0301-472x(99)00094-6

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

Review 1.  The central role of SOCS-3 in integrating the neuro-immunoendocrine interface.

Authors:  C J Auernhammer; S Melmed
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 2.  Negative Regulation of Cytokine Signaling in Immunity.

Authors:  Akihiko Yoshimura; Minako Ito; Shunsuke Chikuma; Takashi Akanuma; Hiroko Nakatsukasa
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

3.  SOCS proteins in development and disease.

Authors:  Monique C Trengove; Alister C Ward
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

Review 4.  Thrombopoietin and hematopoietic stem cells.

Authors:  Carolyn A de Graaf; Donald Metcalf
Journal:  Cell Cycle       Date:  2011-05-15       Impact factor: 4.534

5.  The ubiquitin ligase Cul5 regulates CD4+ T cell fate choice and allergic inflammation.

Authors:  Binod Kumar; Natania S Field; Dale D Kim; Asif A Dar; Yanqun Chen; Aishwarya Suresh; Christopher F Pastore; Li-Yin Hung; Nadia Porter; Keisuke Sawada; Palak Shah; Omar Elbulok; Emily K Moser; De'Broski R Herbert; Paula M Oliver
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

Review 6.  The role of suppressors of cytokine signalling in human neoplasms.

Authors:  Walid Sasi; Anup K Sharma; Kefah Mokbel
Journal:  Mol Biol Int       Date:  2014-03-16

Review 7.  Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy.

Authors:  Shunsuke Chikuma; Mitsuhiro Kanamori; Setsuko Mise-Omata; Akihiko Yoshimura
Journal:  Cancer Sci       Date:  2017-04-19       Impact factor: 6.716

8.  The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8+ T cells.

Authors:  Geoffrey Guittard; Ana Dios-Esponera; Douglas C Palmer; Itoro Akpan; Valarie A Barr; Asit Manna; Nicholas P Restifo; Lawrence E Samelson
Journal:  Sci Rep       Date:  2018-03-28       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.